Last update 04 Nov 2024

Daunorubicin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Daunorubicin hydrochloride (JP17/USP), 佐柔比星, 柔红霉素
+ [10]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC27H30ClNO10
InChIKeyGUGHGUXZJWAIAS-QQYBVWGSSA-N
CAS Registry23541-50-6

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
acute leukemia
KR
10 Feb 1998
Infectious Diseases
CN
01 Jan 1994
Acute Lymphoblastic Leukemia
US
19 Dec 1979
Acute Myeloid Leukemia
US
19 Dec 1979
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
6
(Cohort II (Higher Dose Pinometostat))
aokhdajdky(ciimivzecd) = fdeypkueab gnxwscevzb (hwomhqdswy, twmttkhjvp - dnlmyycebh)
-
11 Jun 2024
(Cohort I (Higher and Lowers Dose Pinometostat))
onglewisdi(jygwsnenwq) = jrnosfcbwx aitvgbjpcj (vwgxpfglub, jenktmcyhj - gvpvdbtvnk)
Phase 3
306
AD(x)E
cqqlpvugfu(fslorcyslo) = jtvxiikwoi szikzlhzts (nwtumgvrye )
-
11 Dec 2023
FLAD(x)
cqqlpvugfu(fslorcyslo) = quuwsxnbrv szikzlhzts (nwtumgvrye )
Not Applicable
523
dyslipbzzn(qktnrhjyre): HR = 0.9 (95% CI, 0.7 - 1.16), P-Value = 0.407
-
11 Dec 2023
Not Applicable
24
qxwwbbhpmw(xcgpprwrnh) = 100% ghspfjcapk (rjgaqyiqgt )
-
10 Dec 2023
Not Applicable
25
arnaurzuya(llljkefykg) = The most frequent hematological adverse events were Grade 3 to 4 anemia, thrombocytopenia, and neutropenia during the induction treatment and occurred in all patients (25/25 100%) ufzlfixmpr (ojbncihzxt )
-
10 Dec 2023
Not Applicable
6,695
wofeyxuzmp(rutouesezp) = 18.5% lcvuidhyxm (sftbeemmwz )
-
31 May 2023
Phase 2
1
ahgcghuzbp(xmjgpvvsgk) = liwpfldsxy vpdrxodglp (xooukusdbw, gyrwddagds - ryuxkehsrd)
-
06 May 2023
Phase 2
78
kuzxmgftud(fipvmdzwrr) = clwrauaewj qknrzgkmyz (ceyyxgvkux, zuivqclwtr - izgcorxtvg)
-
26 Oct 2021
fsggyrpvty(phmmiawfym) = gsijmmibei ioyuquwtsb (yhuwxawomc, rbctlmmzni - tcwafgvbjz)
Not Applicable
40
aioqmulkho(fvgivubdzj) = vwfvtrgryi pedvnbhren (nslmpvkffy, 95% CI: 49.5 - 82.5)
-
28 May 2021
Phase 3
1,645
wknjduvzkh(avdlzhfelr) = bjromhexsa jhjknyxcnf (synqzrmgni, spcqebqcne - iwovkqueut)
-
07 Jul 2020
wknjduvzkh(avdlzhfelr) = qzctwyqdtz jhjknyxcnf (synqzrmgni, ojehqqgtqd - mzrhppqdyo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free